Pardes Biosciences, Inc.
PRDS
$0.02
Change (1 day)
$3.67
Year High
$0.75
Year Low
Categories
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
P/E ratio for Pardes Biosciences, Inc. (PRDS)
P/E ratio as of 2022: -1.05
According to Pardes Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.05. At the end of 2021 the company had a P/E ratio of -1.61.
P/E ratio history for Pardes Biosciences, Inc. from 2020 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -1.05 |
| 2021 | -1.61 |
| 2020 | 0.00 |